Market closedNon-fractional

Supernus Pharmaceuticals/SUPN

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Ticker

SUPN

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Rockville, United States

Employees

652

SUPN Metrics

BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$0.31
EPS
1.01
Beta
-
Dividend rate
$1.4B
1.01
1.73
1.416
3.551
4.534
6.18%
0.23%
-1.68%
2.36
1.52
6.09
14.1
-10.64%
-133.85%
2.40%
-47.21%

What the Analysts think about SUPN

Analyst Ratings

Majority rating from 4 analysts.
Buy

SUPN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.06% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$144M
-12.60%
Net income
$100K
-90.91%
Profit margin
0.06%
-90.91%

SUPN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 22.12%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.49
$0.24
$0.89
$0.46
-
Expected
$0.07
$0.08
$0.55
$0.38
$0.39
Surprise
653.85%
200.00%
60.84%
22.12%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals (SUPN) has a market cap of $1.4B as of July 05, 2024.

What is the P/E ratio for Supernus Pharmaceuticals stock?

The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 0 as of July 05, 2024.

Does Supernus Pharmaceuticals stock pay dividends?

No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Supernus Pharmaceuticals dividend payment date?

Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.

What is the beta indicator for Supernus Pharmaceuticals?

Supernus Pharmaceuticals (SUPN) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Supernus Pharmaceuticals stock

Buy or sell Supernus Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing